Moleculin Announces Data From Phase 2B/3 "MIRACLE" Trial Evaluating Annamycin In Combination With Cytarabine
Benzinga Newsdesk 5 months ago
BiotechNewsGeneral
Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of careFirst 45-subject data unblinding expected before June 30, 2026Program targets
Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of care
First 45-subject data unblinding expected before June 30, 2026
Program targets high-unmet-need AML population, including R/R Venetoclax subjects
Recruitment of Part A continues to the target 90 subjects in Q3 2026 with 56 or 62% subjects recruited and randomized